Alamar Biosciences (NASDAQ:ALMR) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Alamar Biosciences (NASDAQ:ALMR) announced its quarterly earnings data on Monday. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.14, Zacks reports.

Alamar Biosciences Trading Down 1.7%

Shares of Alamar Biosciences stock traded down $0.47 during midday trading on Monday, hitting $27.99. The company had a trading volume of 270,182 shares, compared to its average volume of 298,409. The business has a fifty day moving average price of $24.43. The stock has a market capitalization of $1.94 billion and a PE ratio of -16.09. Alamar Biosciences has a 12-month low of $18.84 and a 12-month high of $29.43.

Analysts Set New Price Targets

A number of analysts have recently commented on ALMR shares. Wall Street Zen upgraded shares of Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target for the company. Bank of America initiated coverage on shares of Alamar Biosciences in a research note on Tuesday, May 12th. They set a “neutral” rating and a $27.00 price objective on the stock. TD Cowen restated a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Finally, Zacks Research raised shares of Alamar Biosciences to a “hold” rating in a research note on Wednesday, May 13th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Alamar Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.